DPP-4 inhibitors have been reported to stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent way causing a low risk of hypoglycaemia and weight gain compared to other antidiabetic agents. This evidence concerns the gene INS and Hypoglycemia.